Initiator Pharma’s CEO Claus Elsborg Olesen comments
“I want to express a big thank you to both new and existing shareholders who have chosen to subscribe for shares in Initiator Pharma’s preferential rights issue. It is gratifying to see the great interest in our company and with the proceeds which this rights issue will provide the company, we can now more fully focus on our development work and our upcoming studies of IPED2015. This is a significantly important effort which we hope will lead to a better life for millions of men and their partners.”
Subscriptions and allotment
Subscriptions for the rights offering were received in the amount of approximately SEK 44,1 million including subscription commitments, which means that 3,721,689 new shares will be issued. Initiator Pharma thus will receive approximately SEK 20.5 million (before issuance costs, which are estimated at about SEK 1.4 million). 3,073,563 shares (corresponding to approx. 82,6 percent) will be allocated to subscribers with preferential rights. Allotments were made in accordance with the allocation principles set forth in the Company’s Swedish Memorandum and Danish Prospectus. The subscribers without preferential rights to whom the shares are allotted will receive contract notes, which are being sent out today, February 15, 2017. Those who have submitted a subscription for shares but who were not allocated shares will not receive contract notes.
Number of shares and amount of share capital
Once Initiator Pharma’s rights issue has been registered with the Erhvervsstyrelsen/Danish Business Authority, the total number of shares outstanding will amount to 8,683,943 and the share capital to DKK 911,814.015.
Listing on AktieTorget
Initiator Pharma A/S has been approved for listing on AktieTorget. March 16, 2017 is the projected date for the first day of trading.
Sedermera Fondkommission is the financial advisor to Initiator Pharma in connection with the rights offering and the listing on AktieTorget.
For more information about the rights offering and the listing on AktieTorget, please contact:
Telephone: +46 (0)40-615 14 10
For additional information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
This information is information that Initiator Pharma A/ is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on February 15th 2017.
A few words about Initiator Pharma
Initiator Pharma is a pharmaceutical company based in Aarhus, Denmark, spun off from Saniona AB (listed on Nasdaq Stockholm First North Premier). The Company’s main focus is the pharmaceutical candidate IPED2015, which constitutes a new treatment for the indication of erectile dysfunction (ED) - the inability of a man to achieve and maintain an erection and thus be able to complete sexual intercourse. Initiator Pharma’s new treatment method with IPED2015 is intended to treat the large group of patients suffering from of erectile dysfunction who are resistant to current treatment methods.